Remarkable new findings about the sugar stores in neurons have unlocked an entire new method of treating Alzheimer's disease ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

Scientists have discovered that the metabolism of glycogen, a sugar stored in neurons, can protect the brain from Alzheimer's disease and cognitive decline.

A small study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide shows a benefit in patients with Alzheimer's disease.

Employers are grappling with the ripple effect of an increasingly popular weight loss treatment. Pharmacy benefit leaders at Holmes Murphy share what to consider when evaluating GLP-1s for your ...

Study comparing bariatric surgery to GLP-1 medications shows 24% total weight loss from surgery versus 4.7% from injectables, ...

Peanuts and peanut butter can be a key dietary element for GLP-1 users because peanuts contain significant amounts of protein, fiber and healthy fats. By The Peanut Institute ...

Semaglutide is marketed under the brand names, such as Ozempic, which is primarily prescribed for those with Type 2 diabetes, and Wegovy, which is commonly prescribed for weight loss. The drug mimics ...

With 182 trials and 138 novel drugs, the 2025 Alzheimer's disease drug pipeline has more activity than it did in 2024, an analysis showed.

Alzheimer's Disease : Alzheimer’s Disease Center of Excellence includes the latest research, journal articles, cases, quizzes, and peer discussion about Alzheimer’s disease.